Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI2 | P48307 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | GMNN | O75496 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | PPM1B | O75688 | 2/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.39 |
| ▸ | PPP1CC | P36873 | 2/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.39 |
| ▸ | PPP5C | P53041 | 2/20 | 0.38 |
| ▸ | PPP2CA | P67775 | 1/20 | 0.38 |
| ▸ | NPY4R | P50391 | 1/20 | 0.38 |
| ▸ | PLG | P00747 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2184711 | 1.00 | TFPI2 (0.52) | TFPI2LMNAKDM4EGMNNPMP22 | |
| SCHEMBL4098788 | 1.00 | TFPI2 (0.52) | TFPI2LMNAKDM4EGMNNPMP22 | |
| SCHEMBL4088843 | 1.00 | TFPI2 (0.52) | TFPI2LMNAKDM4EGMNNPMP22 | |
| SCHEMBL4948347 | 1.00 | TFPI2 (0.52) | TFPI2LMNAKDM4EGMNNPMP22 | |
| SCHEMBL7263479 | 1.00 | TFPI2 (0.52) | TFPI2LMNAKDM4EGMNNPMP22 | |
| SCHEMBL2726787 | 1.00 | TFPI2 (0.52) | TFPI2LMNAKDM4EGMNNPMP22 | |
| SCHEMBL4109815 | 1.00 | TFPI2 (0.52) | TFPI2LMNAKDM4EGMNNPMP22 | |
| SCHEMBL124941 | 1.00 | TFPI2 (0.52) | TFPI2LMNAKDM4EGMNNPMP22 | |
| SCHEMBL2184024 | 1.00 | TFPI2 (0.52) | TFPI2LMNAKDM4EGMNNPMP22 | |
| SCHEMBL27976167 | 1.00 | TFPI2 (0.52) | TFPI2LMNAKDM4EGMNNPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1405852-B9 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2013-03-27 | — | — | EP | disclosed |
| EP-1405852-B1 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2012-08-01 | — | — | EP | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| US-20090270446-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-7365205-B2 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-04-29 | — | — | US | disclosed |
| US-7342014-B2 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20080015215-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270446-A1 | DIAMINE DERIVATIVES | F2, TFPI, F3 | TFPI2 10/4885LMNA 2682/4885KDM4E 588/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | TFPI2 393/4885LMNA 2624/4885KDM4E 3971/4885 |
| US-20080015215-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | TFPI2 393/4885LMNA 2624/4885KDM4E 3971/4885 |
| US-20110312990-A1 | Diamine Derivatives | C9, C1S, C1R | TFPI2 413/4885LMNA 2829/4885KDM4E 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.